To verify a pharmaceutical ingredient supplier’s FDA registration claim, search the FDA’s Drug Establishments Current Registration Site (DECRS), match the record to the actual manufacturing establishment, and confirm that the registered activities fit the supplier’s role. Then assess the ingredient documentation and the facility’s regulatory history separately. A registration record supports a specific administrative claim; it does not establish FDA approval, current good manufacturing practice compliance, or suitability for your intended use.

The first question is which establishment the supplier is asking you to trust. An invoice may come from a distributor, while manufacturing, testing, repackaging, and storage involve other businesses. Verification becomes meaningful only when the claim connects to the physical site responsible for the ingredient you will receive.

Start with the ingredient’s status and the supplier’s actual role

Before searching an FDA database, establish whether you are buying an active pharmaceutical ingredient (API), an excipient, or a material intended for further processing. The phrase “pharma ingredient” does not identify a single regulatory category, and registration obligations depend on the material, activities, and applicable exemptions.

Establishments manufacturing APIs for the U.S. drug market are generally subject to drug establishment registration and listing requirements, unless an exemption applies. A supplier dealing solely in excipients may have a different position. A food facility registration for a substance also sold into pharmaceutical applications does not establish registration as a drug manufacturing establishment.

A distributor may legitimately supply an API without manufacturing it. Its own registration status, however, cannot substantiate the manufacturing site’s status. Similarly, a registered repackager’s record does not establish that the original API manufacturer is registered or adequately qualified.

Ask the supplier to provide a compact identification package before accepting a certificate or database screenshot:

• The legal name and complete physical address of the original manufacturing establishment.
• The name of the selling entity and its relationship to that establishment.
• The FDA Establishment Identifier (FEI), if available, and any other identifier used in the registration submission.
• The activities performed at each relevant site, including manufacturing, repackaging, relabeling, and testing.
• The ingredient name, grade, intended use, and documentation connecting the offered material to its manufacturer.

If the supplier claims an exemption, request the regulatory basis and the facts supporting it. An exemption may explain why a particular entity does not appear in a database. It should not serve as a general answer to questions about an undisclosed manufacturer.

Check the FDA record and reconcile the establishment details

Access DECRS through the FDA’s official website and search using the manufacturer’s legal name. Where the search interface permits, use identifiers or location details to narrow the results. Try reasonable name variations if the supplier uses an abbreviation, a trading name, or a translated company name.

Read the scope and explanatory notes accompanying the database. Public records should be interpreted according to what the FDA says they contain; they are not a complete map of every business involved in pharmaceutical supply.

For a matching record, examine three elements together: establishment identity, location, and registered operations.

Match the legal entity and physical site

A company name alone is a weak match. Large manufacturers can operate multiple facilities under similar names, and a corporate headquarters may differ from the production address. Compare the database location with the manufacturer details in the supplier’s qualification package, quality agreement, and relevant batch documentation.

Minor differences in transliteration or address formatting can be explainable. A different city, industrial park, or production site requires a documented explanation. If the company has changed ownership or legal name, request records connecting the former and present identities.

Check whether the operations support the claim

Review the operations shown in the record. A site identified for repackaging or relabeling does not, on that basis, establish that it manufactures the API. Likewise, a record for one facility cannot support a claim about production at another facility belonging to the same corporate group.

Keep the conclusion narrow. Even where a record identifies drug manufacturing operations, that does not independently establish that a particular ingredient, production line, or batch is covered by the supplier’s representations. The material-to-site connection needs supporting documentation.

Distinguish an identifier from registration status

An FEI helps identify an establishment in FDA systems. Possessing an FEI does not by itself demonstrate a current drug establishment registration. Other identifiers can support identity matching or electronic submissions without proving registration status.

Save the search result, the date checked, and the identifying details used. Drug establishment registration requires periodic renewal, and an old screenshot cannot establish the status applicable to a new purchase. Recheck when onboarding a supplier, when the manufacturing site changes, and at intervals justified by your supplier risk assessment.

If no matching establishment appears, avoid jumping immediately to a fraud conclusion. First resolve spelling, legal-name changes, physical addresses, and the applicable regulatory category. Ask the supplier for its registration submission details and evidence of the FDA’s electronic acknowledgment. Such an acknowledgment can help investigate a discrepancy, but it does not independently prove that all information is accurate or that the establishment remains currently registered.

If the discrepancy persists, seek clarification through the FDA contact channel identified for drug registration and listing questions. Until the identity and status are resolved, record the claim as unsubstantiated in the supplier qualification process.

Understand what certificates and product numbers can establish

A polished “FDA registration certificate” can look more conclusive than the underlying evidence. The FDA does not issue drug establishment registration certificates. Commercial service providers may produce certificates after assisting with submissions, but those documents are private attestations.

A certificate may contain useful search details. Its logo, seal, signature, or expiration date adds no independent regulatory standing. Verify the establishment through the official record and investigate discrepancies using the underlying submission information.

Apply the same discipline to the following claims:

• “FDA approved facility”: Ask which specific FDA action the supplier means. Establishment registration does not confer facility approval.
• “FDA registered product”: Clarify whether the supplier means establishment registration, drug listing, or an approved drug application. These are distinct matters.
• “NDC number available”: A National Drug Code or listing entry does not establish FDA approval or demonstrate acceptable manufacturing quality.
• “DMF available”: A Drug Master File can support regulatory review, but its existence does not mean the FDA has independently approved the ingredient or supplier.

For an API, do not assume that a search of the public NDC Directory will provide a complete answer. The directory has its own scope and limitations and cannot replace establishment verification or an ingredient-specific regulatory assessment. Absence from that directory alone is not a sufficient basis for rejecting an API manufacturer.

If a supplier cites a Drug Master File, clarify its relevance to the exact manufacturer, site, and material. Where your regulatory pathway requires access, address the appropriate authorization with your regulatory team. A DMF number without a usable connection to the proposed supply offers limited procurement assurance.

Review compliance history as a separate question

Once the establishment’s registration is substantiated, assess whether available evidence supports qualifying it for your ingredient. Registration and compliance history answer different questions. An establishment can have a registration record while also having significant quality or enforcement concerns.

Search FDA warning letters, import alerts, and available inspection records using the legal name, previous names, address, and FEI where supported. Check the dates and affected operations. A record concerning a different subsidiary or site should not automatically be attributed to the proposed manufacturer.

Warning letters can identify significant violations and explain the FDA’s concerns. Read the actual letter and any published follow-up, including a closeout letter where available. A closeout reflects the matters addressed in that correspondence; it does not guarantee continuing compliance across every operation.

Import alerts can affect whether covered products may enter the United States without detention. Examine the specific firm, product, and reason. An alert involving the proposed ingredient can create a delivery problem even when the supplier presents a registration record. Conversely, absence from an import alert is not evidence of FDA approval.

Inspection information requires context. FDA inspection classifications include No Action Indicated, Voluntary Action Indicated, and Official Action Indicated. These describe the regulatory assessment of the relevant inspection and should be read alongside its date, scope, and subsequent developments.

A Form FDA 483 records inspectional observations; it is not itself a final agency determination of violations. If observations concern the proposed manufacturing activities, request the supplier’s response, corrective actions, and evidence that those actions were effective. An assertion that an inspection was “passed” is too imprecise to resolve those questions.

Public information has limits. Records may be published after the underlying event, and a search may not reveal every inspection document or communication. A lack of visible enforcement action should therefore lead to ordinary supplier qualification, including an appropriate audit and quality review, rather than an assumption that the FDA has endorsed the site.

Connect the verified site to the material you will purchase

The final check is traceability. A valid registration belonging to a credible manufacturer has little value if the offered batch comes from another source.

Compare the manufacturer identified during verification with the proposed supply chain, certificate of analysis, specifications, and quality agreement. Establish who releases the material, whether it is repackaged, and how original batch identity is preserved. For a distributor, obtain enough documentation to connect the supplied lot to the original manufacturer and identify any intervening processing.

Consider a hypothetical offer supported by a registration record for Site A, while the qualification documents identify Site B as the producer. Both facilities might belong to the same company, but the discrepancy remains material. The supplier should establish which site makes the ingredient and provide the evidence relevant to that location before qualification proceeds.

Use the evidence to make a proportionate decision:

• Proceed with qualification when establishment identity, applicable registration status, activities, and material traceability align. Complete the remaining quality and regulatory assessments before approving supply.
• Hold qualification when name changes, address differences, conflicting documents, or unresolved submission details prevent a reliable match.
• Reject the registration claim when it relies on another establishment’s identity, cannot be substantiated, or is presented misleadingly after clarification has been requested.

Record the conclusion precisely: the named establishment’s registration was checked on a stated date, its identity was matched to the proposed manufacturing site, and specified quality questions were assessed separately. Avoid reducing that work to “FDA-approved supplier.”

Before the first commercial order, establish how the supplier will notify you of manufacturing-site changes, significant regulatory actions, and relevant registration changes. Verification remains useful only while the evidence continues to describe the facility and supply chain behind the ingredient you actually receive.